Lanean...
Novel Therapies in Advanced Renal Cell Carcinoma: Management of Adverse Events From Sorafenib and Sunitinib
INTRODUCTION: Sorafenib and Sunitinib are the first tyrosine kinase inhibitors licensed for the treatment of advanced renal cell carcinoma. In contrast to conventional chemotherapy, targeted therapies have distinct and specific side effects. METHODS: Selective review in Medline and the data base of...
Gorde:
| Egile Nagusiak: | , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Deutscher Arzte Verlag
2008
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2696772/ https://ncbi.nlm.nih.gov/pubmed/19629201 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3238/arztebl.2008.0232 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|